Polypharmacy and Gait Performance in Community–dwelling Older Adults
Open Access
- 26 June 2017
- journal article
- drugs and-pharmacology
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 65 (9) , 2082-2087
Abstract
Objectives: To examine the relationship between polypharmacy and gait performance during simple (normal walk ( NW )) and complex (walking while talking ( WWT )) locomotion. Design: Cross‐sectional. Setting: Community. Participants: Community‐dwelling older adults (N = 482). Measurements: Polypharmacy, defined as use of five or more medications and a cohort‐specific alternate definition of eight or more medications, was examined. Velocity (cm/s) measured quantitatively during NW and WWT conditions. Results: The 164 participants (34%) with polypharmacy of five or more medications were older (77.0 ± 6.6 vs 76.0 ± 6.4) and more likely to have hypertension, congestive heart failure, diabetes mellitus, myocardial infarction, and higher body mass index ( BMI ) and to have fallen within the last year than the remaining 318 without polypharmacy and walked 6 cm/s slower ( P = .004) during NW and 4 cm/s slower during WWT ( P = .07), adjusting for age, sex, and education. Group differences were not statistically significant after adjusting for comorbidities. Prevalence of polypharmacy of eight or more medications was 10%. This group walked 11 cm/s slower during NW ( P < .001) and 8.6 cm/s slower during WWT ( P = .01) than those without polypharmacy, adjusted for age, sex, and education. Participants taking eight or more medications had slower NW (8.5 cm/s; P = .01), and WWT (6.9 cm/s; P = .07), compared to those without polypharmacy, adjusting for comorbidities. Adjustments for BMI , high‐risk drugs, falls, and comorbidities yielded slower NW (9.4 cm/s, P = .005) and WWT (7.9 cm/s, P = .04 among those with polypharmacy compared to those without polypharmacy). Conclusion: These results suggest an association between polypharmacy and locomotion that medical comorbidities only partly explained.Keywords
Funding Information
- National Institute on Aging (R01AG036921-01A1, R01AG044007-01A1, R01 AG039330, RO1AGO44007, RO1 AGO44829, R01AG036921, PO1 AGO3949)
- National Institutes of Health (KL2TR001071)
This publication has 19 references indexed in Scilit:
- Gait Performance in Hypertensive Patients on Angiotensin-Converting Enzyme InhibitorsJournal of the American Medical Directors Association, 2016
- Physical performance measures and polypharmacy among hospitalized older adults: Results from the crime studyThe Journal of nutrition, health and aging, 2014
- Walking while Talking and Falls in AgingGerontology, 2013
- Clinical consequences of polypharmacy in elderlyExpert Opinion on Drug Safety, 2013
- Performance variance on walking while talking tasks: theory, findings, and clinical implicationsAGE, 2013
- Gait and Cognition: A Complementary Approach to Understanding Brain Function and the Risk of FallingJournal of the American Geriatrics Society, 2012
- Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomesJournal of Clinical Epidemiology, 2012
- Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three‐year period in an elderly populationPharmacoepidemiology and Drug Safety, 2011
- Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly PersonsArchives of internal medicine (1960), 2009
- Validity of Divided Attention Tasks In Predicting Falls in Older Individuals: A Preliminary StudyJournal of the American Geriatrics Society, 2002